C-Suite Perspectives on the Mid-Revenue Cycle: New Insights from 80 Health System Leaders
What do CFOs, Chief Revenue Cycle Officers, and other senior RCM executives at health systems ranging from $750M to $15B+ in net patient revenue actually think about the mid-revenue cycle — its risks, its potential, and where AI fits in? Smarter Technologies partnered with The Health Management Academy to find out.
In this webinar, we present fresh survey findings from 80 C-suite RCM decision-makers, 87% of whom hold final or primary investment decision-making authority, offering a rare, unfiltered look at how health system leadership is thinking about Mid-Revenue Cycle Management (MRCM) strategy heading into the next phase of revenue cycle transformation:
Speakers
Michael Nelson SVP, Strategic Services, Universal Health Services
Ruben Amarasingham, MD, Chief Medical Officer, Smarter Technologies
Key Learnings
The rigor of MRCM performance tracking hasn't kept pace with strategy. While MRCM is a C-suite priority, most organizations still can't systematically quantify mid-cycle inefficiency costs. Close that gap first.
Upstream failures drive downstream losses, yet a majority of systems still maintain a reactive posture. Key threats, like medical necessity denials and prior auth breakdowns, start before discharge—and so should revenue integrity interventions.
Shared dashboards aren't shared accountability. Restructure clinical-RCM incentives around joint outcomes and mutual definitions, not just joint reporting.
AI ROI expectations are specific and increasingly defined — hold vendors to them. Systems must focus on concrete metrics on denial reduction, clean claim rates, and EHR integration timelines before signing.